Published in Cancer Weekly, August 13th, 2002
Typically, the midpoint of known survival time is 6 months for end-stage lung cancer patients who, like her, have failed conventional treatments such as surgery or chemotherapy. The patient experienced no significant side effects during treatment.
She received Advexin in 1997 as part of a phase I trial at The University of Texas M. D. Anderson Cancer Center in Houston after being diagnosed with metastatic non-small cell lung cancer. The patient's tumor could not be surgically removed...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.